X
- No products in the list
The Lung Cancer Panel from TRUPCR® enables accurate detection of EGFR mutations, PIK3CA mutations, and ALK fusions from FFPE tissue samples using Real-Time PCR. This kit provides a complete solution for laboratories, including reagents, controls, and validated workflows compatible with widely used PCR platforms. With its high sensitivity and specificity, the TRUPCR® Lung Cancer Mutations Panel Kit supports reliable molecular diagnostics, guiding targeted treatment strategies such as EGFR tyrosine kinase inhibitors and ALK inhibitors. Designed for clinical chemists, molecular diagnostics experts, and oncology researchers, this assay ensures confidence in mutation profiling for lung cancer patients.
The Lung Cancer Panel is a diagnostic molecular tool that enables the detection of common mutations and fusions linked to lung cancer progression and therapy response. This kit identifies mutations in EGFR (exons 18–21), PIK3CA (exons 7, 9, 20), and fusions in the ALK gene from FFPE tissue samples. These biomarkers are essential in predicting tumor behavior and guiding precision therapies.
Lung cancer remains the leading cause of cancer-related mortality globally, and precise molecular diagnostics are crucial to improve survival outcomes. The TRUPCR® panel consolidates multiple critical targets into one streamlined workflow.
EGFR Mutations: Found in exons 18–21, mutations like L858R, T790M, and Ex20ins are associated with responsiveness or resistance to EGFR tyrosine kinase inhibitors.
PIK3CA Mutations: Commonly detected in exons 7, 9, and 20, PIK3CA mutations activate the PI3K/AKT signaling pathway, contributing to tumor progression and resistance mechanisms.
ALK Fusions: ALK rearrangements result in constitutive kinase activation and uncontrolled growth. Detecting ALK fusions is critical for identifying patients eligible for ALK inhibitor therapies.
Together, these markers form the foundation for personalized treatment decisions in non-small cell lung cancer (NSCLC).
The TRUPCR® kit is designed as an all-in-one molecular diagnostic solution:
Targets EGFR, PIK3CA, and ALK with a high degree of accuracy
Validated for use with formalin-fixed paraffin-embedded (FFPE) tissue samples
Includes all necessary reagents and controls, reducing workflow complexity
Compatible with widely adopted PCR systems: Applied Biosystems™, QuantStudio®, Rotor-Gene Q, Bio-Rad CFX96/384, AriaMx, and Roche LightCycler® 480-II
By providing reproducible results, the kit helps clinicians and laboratories deliver actionable data to support patient care.
The TRUPCR® Lung Cancer Panel uses Real-Time PCR to detect mutations and fusions.
DNA/RNA Extraction from FFPE tissue
Amplification using mutation- and fusion-specific primers
Detection via fluorescent probes across multiple channels
Result Analysis to identify specific mutation/fusion profiles
This streamlined process ensures rapid turnaround and highly specific results without the need for complex sequencing workflows.
The TRUPCR® Lung Cancer Panel is essential for:
Diagnostic profiling of lung cancer patients
Treatment guidance for EGFR-targeted therapies and ALK inhibitors
Resistance monitoring for mutations such as EGFR T790M
Research applications in oncology and drug resistance
Its high sensitivity enables detection of clinically relevant mutations even in samples with limited DNA/RNA availability, supporting better patient stratification and therapy outcomes.
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.